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Abstract 
Background: Systemic lupus erythematosus (SLE) is an autoimmune‑mediated chronic inflammatory disease. Half of 
patients with SLE suffer from lupus nephritis, which is major cause of death in SLE. TNF‑like weak inducer of apoptosis 
(TWEAK)/fibroblast growth factor‑inducible 14 (Fn14) interactions mediate inflammatory responses that are linked to 
the pathogenesis of lupus nephritis. Blocking of the TWEAK/Fn14 pathway by Fn14‑Fc was performed in a SLE mouse 
model and the likely therapeutic mechanisms were investigated.
Methods: To investigate the impact of TWEAK on B cell differentiation in SLE, the levels of AID, Blimp‑1, and IRF4 mes‑
senger RNA were measured in CD19+ B cells extracted from the spleens of sanroque mice and cultured with TWEAK. 
To identify the therapeutic effects of Fn14‑Fc in SLE, sanroque mice were treated with Fn14‑Fc or a control‑Fc for 
3 weeks. Immunoglobulin (Ig) G, IgG1, IgG2a, and anti‑dsDNA antibody (Ab) levels were measured in the sera of each 
group. Spleens from each group were stained with antibodies against CD4, B220, GL‑7, CD138, and PD‑1. Kidneys 
were stained with hematoxylin and eosin (H&E) and periodic acid‑Schiff (PAS).
Results: Administration of TWEAK increased the mRNA levels of AID, Blimp‑1, and IRF4. Treatment with Fn14‑Fc sup‑
pressed levels of IgG, IgG1, IgG2a, and anti‑dsDNA Ab in sera and reduced numbers of B, plasma, and follicular helper 
T (Tfh) cells in spleens of sanroque mice. In addition, renal protective effects of Fn14‑Fc were shown.
Conclusion: Fn14‑Fc had beneficial effects in a SLE mouse model by repressing B cells, plasma cells, Tfh, and renal 
damage. This suggested that Fn14‑Fc represents a potential therapeutic agent for SLE.
Keywords: TNF‑like weak inducer of apoptosis (TWEAK), Fibroblast growth factor‑inducible 14 (Fn14), Systemic lupus 
erythematosus (SLE), Germinal center (GC), Follicular helper T (Tfh) cell
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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease that can damage many organ systems 
[1]. Several heterogenic factors, including genetic, epi-
genetic, environmental, and immunoregulatory compo-
nents, contribute to the development of SLE [1]. Aberrant 
immune reactions in SLE are mediated by autoantibodies 
(autoAbs), immune complexes and autoreactive inflam-
matory cells, which result in organ damage. Females of 
childbearing age constitute the majority of SLE patients, 
and approximately half of SLE patients have kidney 
involvement. Lupus nephritis is a major cause of mortal-
ity and morbidity in SLE [2].
Autoantibodies and immune complexes play a cru-
cial role in tissue damage and inflammatory responses 
in SLE. Plasma cells derived from B cells produce anti-
bodies (Abs). Germinal centers (GCs) are the secondary 
lymphoid tissue in which B cell selection, differentia-
tion, and maturation occur. In the GC, follicular helper 
T (Tfh) cells play an important role in B cell selection and 
differentiation toward plasma cells [3]. In SLE patients, 
dysregulation of Tfh in the GC plays a crucial role in the 
expansion of self-reactive B cells and the production of 
autoAbs [4]. Roquin protein regulates the development 
of Tfh in the GC, and a mutation of the sanroque gene 
results in excessive formation of Tfh and GC [5]. Roquin-
San/San mice were selected as a SLE model in this study 
because the sanroque gene mutation causes lupus-like 
features through regulating Tfh and GC.
TNF-like weak inducer of apoptosis (TWEAK) is a pro-
inflammatory cytokine that mediates several cellular and 
inflammatory responses by binding to fibroblast growth 
factor-inducible 14 (Fn14, also known as the TWEAK 
receptor). Recently, a link has been identified between the 
pathogenesis of several autoimmune disorders includ-
ing autoimmune encephalitis, rheumatoid arthritis, and 
SLE with the TWEAK/Fn14 pathway [6, 7]. Xia et  al. 
[8] demonstrated that the TWEAK/Fn14 pathway has a 
crucial role in the pathogenesis of Ab-induced nephritis, 
and disrupting the TWEAK/Fn14 pathway is a potential 
treatment for Ab-induced nephritides, including lupus 
nephritis. Recent studies revealed that the TWEAK/
Fn14 interaction has an important role in the pathogen-
esis of several SLE manifestations [7, 9]. The TWEAK/
Fn14 pathway contributes to the pathogenesis of SLE by 
modulating the local environment of the target organ 
[7, 10]. However, the TWEAK/Fn14 pathway activates 
nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) signaling and the dysregulation of NF-κB 
signaling can induce autoimmune disorders by altering B 
and T cell immunity [11]. Therefore, the TWEAK/Fn14 
interaction may have systemic effects on the pathogen-
esis of SLE in addition to local pathological effects.
We hypothesized that blocking the TWEAK/Fn14 path-
way via administration of Fn14-Fc would attenuate the 
autoimmune response in a mouse model of SLE. To iden-
tify the mechanisms involved, we explored the effects of 
Fn14-Fc on Ab secretion, B cell maturation, Tfh cell devel-
opment, GC formation and kidney damage. In addition, 
the pathologic role of TWEAK was investigated in san-
roque mice by administration of TWEAK to B cells.
Methods
Animals
Roquinsan/san (sanroque) mice in a C57BL/6 background 
were obtained from the National Institutes of Health 
(Bethesda, MD, USA). The mice were maintained under 
specific pathogen-free conditions at the Catholic Research 
Institute of Medical Science at the Catholic University 
of Korea and were fed standard mouse chow (Ralston 
Purina, St. Louis, MO, USA) and water ad  libitum. All 
experimental procedures were examined and approved 
by the Animal Research Ethics Committee of the Catholic 
University of Korea; the procedures conformed to all the 
USA National Institutes of Health guidelines.
Preparation of Fn14‑Fc
The Fn14-Fc and control-Fc used in the experiments (the 
hinge-CH2-CH3 form of IgG1) were bought from A&RT 
Therapeutics (Daejeon, South Korea).
Murine B cell isolation and stimulation
Spleen cells were washed with phosphate-buffered 
saline (PBS; pH 7.2). After centrifugation at 1300  rpm 
and at 4  °C, the cells were incubated with CD19-coated 
magnetic beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) and isolated on MACS separation columns 
(Miltenyi Biotec). Positively selected CD19+ B cells were 
stimulated with TWEAK (0.1 ng/ml; R&D Systems, Min-
neapolis, MN, USA) for 3 days. Total RNA was extracted 
using the TRI Reagent (Molecular Research Center, Cin-
cinnati, OH, USA).
Treatment with Fn14‑Fc
To assess the influence of Fn14-Fc on the severity of 
symptoms in the SLE model, sanroque mice were treated 
with 100  μg/mouse Fn14-Fc in saline or control-Fc via 
intraperitoneal injections three times weekly for 3 weeks. 
Treatment was started in 12-week-old sanroque mice. 
The groups were sacrificed 21 days after the first injection 
and the spleen and kidney were obtained at the time of 
sacrifice.
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Measurement of immunoglobulin (Ig) G subtypes 
and autoAbs
Blood was obtained from the orbital sinus of Fn14-Fc 
and control-Fc-treated mice and the serum was stored 
at −20  °C until use. Total IgG, IgG1, IgG2a, and anti-
double-stranded (ds) DNA Abs were measured using a 
mouse total IgG, IgG1 and IgG2a enzyme-linked immu-
nosorbent assay (ELISA) quantitation kit (Bethyl Labo-
ratories, Montgomery, TX, USA). Anti-dsDNA was 
measured using double-stranded DNA–cellulose from 
calf thymus (Sigma, St. Louis, MO, USA) and an ELISA 
quantitation kit. Levels of total IgG, IgG1 and IgG2a were 
measured in mouse serum diluted 50,000-fold and the 
anti-dsDNA Ab was diluted 10-fold. The optical density 
(OD) at a wavelength of 450 nm of each well was meas-
ured using an ELISA plate reader (Bio-Rad, Hercules, 
CA, USA).
Confocal microscopy
Spleen tissues were snap-frozen in liquid nitrogen and 
stored at −70 °C. Spleen tissue Sections (7 μm) were fixed 
in acetone and stained with Percp-Cy5.5 conjugated anti-
CD4, APC-conjugated anti-B220, PE conjugated anti-
PD-1 and anti-hu/mo CD266 (TWEAKR) (eBioscience, 
San Diego, CA, USA), FITC-conjugated anti-GL-7 and 
PE-conjugated anti-CD138 (BD Biosciences, San Jose, 
CA, USA). Stained sections were visualized using a Zeiss 
microscope (LSM 510 Meta; Carl Zeiss, Oberkochen, 
Germany) at ×400 magnification. The areas of GC and 
Tfh were analyzed per ×400 field on each section using 
ZEN 2009 Light Edition software. To eliminate section-
ing artifacts, sections that were five slices apart were ana-
lyzed in each group.
Histopathological and morphometric analysis
Mice were euthanized and their kidneys were harvested, 
fixed in 10  % buffered formalin, processed for paraffin 
embedding, cut into 5-µm tissue sections, and stained 
with hematoxylin and eosin (H&E) and periodic acid-
Schiff (PAS). Tubular injury and glomerular matrix 
expansion was scored by a blinded assessor on 20 random 
glomeruli from each mice. The following scoring system 
was used: 0 (none), 1 (<25 % glomerular area involved), 2 
(25–50 %), 3 (50–75 %), 4 (75–90 %), and 5 (>90 %).
Real‑time polymerase chain reaction (PCR)
Messenger RNA (mRNA) was extracted using TRI rea-
gent (Molecular Research Center), according to the 
manufacturer’s instructions. Complementary DNA was 
synthesized using the SuperScript reverse transcription 
system (Takara, Otsu, Japan). A Light-Cycler 2.0 (soft-
ware ver. 4.0; Roche Diagnostics, Basel, Switzerland) 
was used for the PCR amplification. All reactions were 
performed with a LightCycler FastStart DNA Master 
SYBR Green I kit (Takara), according to the manufac-
turer’s instructions. The following primers were used: 
activation-induced deaminase (AID), 5′-GCC ACC 
TTC GCA ACA AGT CT-3′ (sense), 5′-CCG GGC ACA 
GTC ATA GCA C-3′ (antisense); X-box binding protein 
1 (xbp-1), 5′-GAT CCT GAC GAC GTT CCA GA-3′ 
(sense), 5′-ACA GGG TCC AAC TTG TCC AG-3′ (anti-
sense); B lymphocyte-induced maturation protein-1 
(Blimp-1), 5′-CTG TCA GAA CGG GAT GAA CA-3′ 
(sense), 5′-TGG GGA CAC TCT TTG GGT AG-3′ (anti-
sense); interferon regulatory factor-4 (IRF4), 5′-GCA 
GCT CAC TTT GGA TGA CA-3′ (sense), 5′-AGG CCA 
AAC GTC ACA GGA CAT TG-3′ (antisense); β-actin, 
5′-GTA CGA CCA GAG GCA TAC AGG-3′ (sense), 
5′-GAT GAC GAT ATC GCT GCG CTG-3′ (antisense), 
Tnfrsf 12a (Fn14), 5′-GGC GCT GGT TTC TAG TTT 
CCT-3′ (sense), 5′-CAG TCT CCT CTA TGG GGG TAG 
T-3′ (antisense) and designed via using Primer Express 
(Applied Biosystems, Foster City, CA). mRNA levels were 
normalized to that of β-actin.
Statistical analysis
The statistical analyses were performed using GraphPad 
Prism (ver. 5 for Windows; GraphPad Software). Numeri-
cal data were compared between the two groups using 
Student’s t-tests. A value of P < 0.05 was taken to indicate 
statistical significance.
Results
TWEAK promotes B cell differentiation in sanroque mice
To assess the effect of TWEAK on B cell differentiation, 
CD19+ cells were extracted from the spleens of sanroque 
mice and cultured with or without TWEAK (0.1 ng/ml). 
After 3 days, total RNA was extracted from the cultured 
cells. In the TWEAK-administrated group, expression 
levels of B cell maturation and differentiation-associated 
genes, including AID, Blimp-1, and IRF4 were signifi-
cantly higher than in the control group (Fig.  1a). These 
results showed that TWEAK promoted B cell differentia-
tion in SLE mouse models and that TWEAK could play 
an important role in aberrant humoral immunity in SLE. 
Fn14 expression was assessed by real-time PCR and con-
focal staining in the spleen. The level of Fn14 mRNA was 
significantly higher in B cells than whole splenocytes and 
T cells (Fig. 1b). In addition, Fn14 expression on spleen B 
cells was confirmed by confocal staining (Fig. 1c).
Suppression of Ig production, GC formation, and B cell 
differentiation in sanroque mice by Fn14‑Fc
Sanroque mice were treated with Fn14-Fc or control-
Fc (100 μg/mouse) three times per week for 3 weeks by 
intraperitoneal injection. Mice were sacrificed 21  days 
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after the first injection. Levels of Ig were measured in 
the sera of each group. The IgG, IgG1, IgG2a, and anti-
dsDNA levels of the Fn14-Fc-treated group were signifi-
cantly lower than those of the control-Fc-treated group 
(Fig. 2a, b).
Spleens extracted from each group were stained with 
Abs against CD4 (white), B220 (blue), GL-7 (green), and 
CD138 (red). mRNA levels were determined by real-time 
PCR of the splenocytes from each group. Spleens from 
Fn14-Fc-treated mice demonstrated reduced numbers of 
B220+, GL-7+, and CD138+ cells, but not of CD4+ cells 
(Fig.  3a). Fn14-Fc administration significantly reduced 
the mRNA levels of xbp-1, Blimp-1, and IRF4. Expression 
of AID mRNA was suppressed in the Fn14-Fc group, but 
the difference was not statistically significant (Fig.  3b). 
Fn14-Fc efficiently repressed Ab production, GC forma-
tion, and differentiation of B cells in sanroque mice.
Fn14‑Fc reduces the Tfh cell population in the spleens 
of sanroque mice
Sanroque mice were treated with Fn14-Fc or control-Fc 
and sacrificed as above. The spleens from both groups 
Fig. 1 TWEAK promotes B cell differentiation. a CD19+ B cells isolated from the spleens of sanroque mice were cultured with or without TWEAK 
(0.1 ng/ml). After 3 days, total RNA was extracted using the TRI reagent. The mRNA levels of various B cell differentiation markers—such as AID, 
Blimp‑1, IRF4—were analyzed by real‑time PCR. b Splenocytes, CD4+ T cells, and CD19+ B cells were isolated from the spleens of sanroque mice, 
total RNA was extracted using TRI reagent, and mRNA levels of Fn14 were analyzed by real‑time PCR. c Spleens from the sanroque mice were 
examined by immunofluorescence staining with monoclonal Abs against B220 (blue) and Fn14 (red). Data are expressed as means ± SDs. *P < 0.05, 
***P < 0.001 compared to the control group
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were stained with Abs against CD4 (white), B220 (blue), 
GL-7 (green), and PD-1 (red). Immunofluorescence 
staining showed a reduction in the numbers of B220+, 
GL-7+, and PD-1+ cells in Fn14-Fc-treated mice com-
pared to control-Fc-treated mice (Fig.  4). This finding 
suggested that Fn14-Fc could suppress not only B cell 
formation but also Tfh cell differentiation in GC.
Fn14‑Fc improves nephritis in SLE mice
The kidneys were extracted from sanroque mice treated 
with Fn14-Fc or control-Fc for 3 weeks (with a treatment 
schedule and sacrifice protocol performed as described 
above). The kidneys were stained with H&E and PAS. The 
structures of the glomeruli and tubules were preserved in 
the Fn14-Fc group, whereas the control-Fc group showed 
deterioration (Fig. 5a). IgG deposition and urinary albu-
min excretion were significantly lower in the Fn14-Fc 
group than in the control-Fc group (Fig. 5b, c). These dif-
ferences indicate that Fn14-Fc has beneficial effects on 
nephritis in SLE mouse models, which spontaneously 
developed glomerulonephritis and renal tubular damage.
Discussion
The results of this study showed that blocking the 
TWEAK/Fn14 pathway using Fn14-Fc showed therapeu-
tic effects in a SLE mouse model. The therapeutic effects 
could be explained by three mechanisms; the major 
mechanism was suppression of B cell differentiation 
and GC formation; inhibition of Tfh cell proliferation; 
and prevention of renal damage in a SLE mouse model. 
Fig. 2 In vivo effect of Fn14‑Fc on Ig production in SLE mice. Sanroque mice were injected intraperitoneally with Fn14‑Fc (100 μg/mouse) or 
control‑Fc (100 μg/mouse) (n = 5/group) for 3 weeks. Mice were sacrificed on day 21 after the first injection. The serum total IgG, IgG1 and IgG2a 
levels were determined by ELISA. Data are expressed as means ± SDs. *P < 0.05, **P < 0.01 compared to the control‑Fc treated group
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Fig. 3 Effects of Fn14‑Fc on GC formation and B cell transcription factors in SLE mice. a Fn14‑Fc or control‑Fc‑treated mice were sacrificed 21 days 
after the first injection. Spleens from the mice in each group (n = 5/group) were examined by immunofluorescence staining with monoclonal 
Abs against CD4 (white) and B220 (blue), GL‑7 (green) and CD138 (red) (original magnification, ×400). b mRNA levels of AID, xbp‑1, Blimp‑1 and IRF4 
in isolated splenocytes were determined by real‑time PCR. Data are expressed as means ± SDs. *P < 0.05, **P < 0.01 compared to the control‑Fc 
treated group
Fig. 4 Fn14‑Fc reduced Tfh cell populations. Fn14‑Fc or control‑Fc‑treated mice were sacrificed 21 days after the first injection. Spleens from mice 
in each group (n = 5/group) were examined by immunofluorescence staining with monoclonal Abs against CD4 (white), B220 (blue), GL‑7 (green), 
and PD‑1 (red). Original magnification ×400
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Additionally, a novel pathological role for TWEAK on 
SLE in which TWEAK promoted B cell maturation was 
revealed.
TWEAK belongs to the TNF ligand family and is a pro-
inflammatory cytokine [12]. Dysregulated and overacti-
vated TWEAK/Fn14 interactions induced inflammatory 
Fig. 5 Fn14‑Fc improved nephritis in SLE mice. Sanroque mice were injected intraperitoneally with Fn14‑Fc (100 μg/mouse) or control‑Fc (100 μg/
mouse) (n = 5/group) for 3 weeks. Mice were sacrificed on day 21 after the first injection. Sections of kidney tissue were stained with H&E (a) and 
PAS (b). Original magnification ×400
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responses and tissue remodeling, which could induce 
autoimmune and chronic inflammatory disease [13, 14]. 
Fn14 is expressed in many tissues, but especially in the 
kidneys. TWEAK/Fn14 interactions play an important 
pathogenic role in Ab-induced nephritis in a mouse 
model [8]. Recent studies showed an association between 
the activities of lupus nephritis and levels of urinary 
TWEAK, and suggested that urinary TWEAK could 
act as a biomarker for lupus nephritis [15–17]. Further-
more, administration of TWEAK to human kidney cells 
induced processes featured in glomerulonephritis by 
promoting expression of inflammatory mediators, infil-
tration of inflammatory cells and proliferation of kid-
ney cells [18]. The TWEAK/Fn14 pathway represents a 
potential therapeutic target for lupus nephritis [19, 20]. 
This study examined the renoprotective effects of Fn14-
Fc in a SLE mouse model.
The relationship between SLE pathogenesis and the 
TWEAK/Fn14 pathway has been the subject of much 
discussion in the fields of lupus nephritis, neuropsychiat-
ric lupus, and vascular injury in SLE [19]. A deficiency of 
TWEAK induced by mutation resulted in Ab deficiency, 
as reported in a recent case that suggested that TWEAK 
regulates B cell differentiation by controlling BAFF acti-
vation [21]. We examined the influence of TWEAK on 
BAFF, and confirmed that BAFF mRNA was upregulated 
by TWEAK stimulation and reversed by a TWEAK-neu-
tralizing monoclonal Ab (not shown). However, these 
data are insufficient to prove that TWEAK stimulates B 
cell differentiation solely by affecting BAFF activation. To 
date, the pathologic effects of TWEAK on the maturation 
and function of B cells have not been fully explained. In 
this study, administration of TWEAK to splenic CD19+ 
cells from sanroque mice increased the expression of B 
cell-associated genes, including AID, Blimp-1, and IRF4. 
Each of these genes is critical for B cell differentiation 
and functions, including maturation, Ab diversification, 
plasma cell generation, and GC formation. We showed 
that Fn14 is highly expressed by B cells, and this sug-
gests that TWEAK controls the proliferation of B cells, 
GC, and Tfh in SLE pathogenesis by directly affecting B 
cells via the TWEAK/Fn14 interaction. Further stud-
ies are needed to clarify the mechanisms of TWEAK in 
SLE pathogenesis. Nevertheless, this study is the first to 
clarify the pathogenic role of TWEAK in B cells by up-
regulation of associated genes and to show Fn14 expres-
sion on B cells.
Circulating autoAbs and immune complexes are a 
pathologic factor of SLE and play a critical role in its 
pathogenesis. Pathogenic autoAbs are produced from 
auto-reactive plasma cells differentiated from B cells 
of GC. Tfh cells have been identified as a subtype of 
CD4+  T cells distinct from type 1 helper T cells (Th1) 
and Th2. The majority of Tfh cell resides in the GC and 
play important roles in GC-induction, selection of B cells 
in the GC, generation of memory B cells and long-lived 
plasma cells from selected B cells, and the production 
of high-affinity Abs [22]. Tfh cells are characterized by 
expression of PD-1, CXCR5, SAP, and ICOS on the cell 
surface [23]. The aforementioned roles of Tfh cell suggest 
that aberrant Tfh in autoimmune disease selects auto-
reactive B cells to mature in GC and become plasma cells, 
which then produce high-affinity pathogenic autoAbs 
[24]. Furthermore, inhibition of aberrant Tfh cell func-
tions has potential as a new therapeutic target for SLE 
[4]. In this study, Fn14-Fc was shown to suppress Tfh cell 
proliferation in vivo in sanroque mice.
In present study, we could show that blocking 
TWEAK/Fn14 signaling by Fn14-Fc suppressed B cell 
and Tfh cell activation and eventually manifestation of 
SLE in sanroque mice. It is not clear that which factor (B 
cell maturation versus Tfh cell differentiation) is more 
important on beneficial effects of Fn14-Fc in SLE mice. 
Futher study of TWEAK/Fn14 signaling on SLE could 
clarify aforementioned issue.
Conclusions
In conclusion, Fn14-Fc had therapeutic effects in the 
sanroque mouse SLE model. Fn14-Fc suppressed the 
development of the GC, B cells, plasma cells, and 
Tfh  cells. As a result, Ig secretion was repressed in 
Fn14-Fc treated sanroque mice. Additionally, glomeru-
lonephritis and renal tubular damage in sanroque mice 
was improved by Fn14-Fc treatment. These results are 
worthy because they demonstrate for the first time that 
blocking the TWEAK/Fn14 pathway regulates systemic 
autoimmunity in SLE mice. Fn14-Fc treatment repre-
sents a potential therapeutic option in SLE, and espe-
cially in lupus nephritis.
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